Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.（TRDA）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
trda · 股价预测 · 5 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 5 位华尔街分析师
Buy
5 位分析师
共识
评级分布
12 个月目标价
High
$21.00
Consensus
$16.00
+155.6% upside
Low
$10.00
Median: $17 · Last Close: $6.26
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$16.00
155.6% upside
High Target
$21
235.5%
Low Target
$10
59.7%
Current Price
$6.26
as of today
Based on analyst price targets, the TRDA stock price prediction for the next 12 months ranges from $10 to $21. The consensus TRDA price forecast of $16.00 implies 155.6% upside from the current price of $6.26.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $6.23 | ↓ 0.42% |
1-day model range: $6.1–$6.37. Peak: $6.37 (-0.42%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $8 | +27.0% |
| 2028 | $9 | +44.1% |
| 2029 | $10 | +53.8% |
| 2030 | $10 | +59.0% |
| 2031 | — | +61.6% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TRDA · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-08 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-04-06 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-02-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-06 | Oppenheimer | Maintains | Outperform→Outperform |
| 2024-08-26 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Entrada Therapeutics, Inc. (TRDA) stock. Of the recent 25 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover TRDA.
分析师推荐趋势
TRDA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$20M
↓ 64.7% YoY
Revenue Next Year
$29M
↑ 49.6% YoY
EPS This Year
$-3.96
EPS Next Year
$-3.58
↓ 9.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast TRDA EPS of $-3.96 for the current fiscal year, based on estimates from 6 analysts. The TRDA revenue forecast is $20M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
TRDA 股价预测由两类独立数据源支撑：来自 5 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。TRDA 的共识目标价为 $16.00（+155.6% 上行空间），分析师共识为 Buy。
TRDA 的短期预测（明日）为 $6.23（-0.42%）。 TRDA 对 2027 年的股价预测均值为 $8。 TRDA 对 2030 年的预测区间为 $8–$12。
Entrada Therapeutics, Inc. 在 NASDAQ 上市，代码 TRDA。TRDA 在 2027 年的整体展望偏积极，在覆盖分析师中约 60% 对应 Buy 共识。
常见问题
TRDA 预测 · 8 个问题根据 5 位华尔街分析师，TRDA 的 12 个月平均目标价为 $16.00，最高 $21.00、最低 $10.00。若有图表，中位目标价可在上方查看。相对当前价 $6.26，隐含约 +155.6% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.